Revolution Medicines began shipping its investigational pancreatic cancer drug daraxonrasib under an FDA-authorized early access program, CEO Mark Goldsmith said. The therapy is not yet approved, but Revolution tied the surge in demand to striking Phase 3 results previously reported in which patients lived nearly twice as long as those receiving standard chemotherapy. The move signals a high-urgency commercialization step that can materially affect physician utilization while regulatory review is ongoing. For companies targeting pancreatic cancer, it also reinforces the market impact of large Phase 3 overall survival signals. Early access distribution may further accelerate real-world uptake and patient access ahead of a formal approval pathway.